Advertisement
CABA vs CGEM
Which Stock Would AI Choose? Cabaletta Bio (CABA) vs. Cullinan Therapeutics (CGEM) Stock Comparison
Key Takeaways
- Cabaletta Bio (CABA) is a clinical-stage cell therapy company focused on engineered T-cell (CAR T) treatments for autoimmune diseases, while Cullinan Therapeutics (CGEM) runs a diversified pipeline of T-cell engagers spanning both autoimmune disease and oncology.
- Cullinan has progressed further toward commercialization, with a positive Phase 3 result and a New Drug Application (NDA) under review for its lead oncology asset, zipalertinib, whereas Cabaletta remains earlier-stage in clinical development.
- Both names carry a "Strong Buy" analyst consensus, but Cullinan's broader catalyst calendar and late-stage regulatory path have supported stronger recent relative performance and a larger market capitalization.
- Sentiment for both stocks is driven heavily by binary clinical and regulatory readouts, making each a high-volatility, catalyst-dependent holding.
- For more detail on these tickers' major news and today's price moves, explore the CABA Major News and CABA Today's Price Move pages, along with the CGEM Major News and CGEM Today's Price Move pages.
- To see how AI-driven systems are currently positioned across the market, visit the Trending AI Robots page.
Introduction
Investors evaluating high-growth biotechnology names often weigh a single-asset story against a diversified pipeline. This stock comparison of CABA (Cabaletta Bio) and CGEM (Cullinan Therapeutics) examines that trade-off directly. Both are clinical-stage developers advancing next-generation immune-based therapies, and both have experienced sharp sentiment swings tied to data releases, financing events, and regulatory milestones. The comparison is most relevant to growth-oriented and thematic investors who follow the autoimmune and oncology innovation cycle, as well as to traders seeking to understand how relative performance and market positioning differ between two similarly sized clinical-stage peers.
CABA Overview and Recent Performance
Cabaletta Bio is a clinical-stage biotechnology company developing engineered T-cell therapies for B cell-mediated autoimmune diseases. Its lead program, rese-cel, is a CD19-directed CAR T cell therapy being evaluated across a RESET clinical development program spanning multiple autoimmune indications. In recent weeks, the company has focused investor attention on manufacturing and data execution: it announced a 10-year commercial supply agreement with Cellares to automate production, and it raised roughly $150 million in an underwritten offering that included participation from Eli Lilly and institutional investors. Recent market activity has also featured clinical data presentations at major medical congresses, including early preconditioning-free lupus findings. These developments have supported a generally constructive but volatile tape, with the stock's year-to-date gain contrasting against pronounced single-day and short-term swings. Cash burn and a single-asset risk profile remain the key considerations shaping sentiment.
CGEM Overview and Recent Performance
Cullinan Therapeutics is a clinical-stage biopharmaceutical company building a portfolio of T-cell engagers aimed at both autoimmune diseases and cancer. Its most advanced asset, zipalertinib, targets non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations. In recent months, the company reported positive Phase 3 results from its REZILIENT3 trial and initiated a rolling NDA submission under the FDA's Real-Time Oncology Review program, with a separate accelerated-approval NDA for zipalertinib monotherapy already under review. The company has also advanced CLN-049 into a registrational Phase 2 study in acute myeloid leukemia (AML) and shared early autoimmune data for CLN-978. This dense catalyst schedule has driven substantial share-price appreciation over the past year, though the stock has also shown meaningful pullbacks during broader sector softness, illustrating the two-sided nature of its momentum.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of AI trading bots from a much larger library of automated strategies. Tickeron offers hundreds of AI trading bots that collectively trade thousands of different tickers, each with its own trading style, strategy, timeframe, performance record, and set of underlying securities. Rather than listing every bot, the Trending AI Robots section surfaces only those judged most suitable for current market conditions, helping traders quickly identify automated approaches that align with prevailing momentum and volatility regimes. Because no two bots are alike, the page serves as a practical starting point for comparing data-driven strategies. You can explore the current selection at the Trending AI Robots page to see which automated systems are drawing attention now.
Head-to-Head Comparison
The core contrast between these two names is pipeline breadth and stage of development. CABA is essentially a single-asset cell therapy story concentrated on autoimmune disease, with substantial upside if rese-cel succeeds but little diversification to offset a clinical setback. CGEM spreads risk across oncology and immunology, with a late-stage lung cancer asset already under regulatory review plus earlier autoimmune programs. This difference shows up in market positioning: Cullinan carries a larger market capitalization and a more crowded, forward-looking catalyst calendar, while Cabaletta trades at a lower valuation with a leaner, higher-beta profile. On growth drivers, Cullinan's near-term catalysts are regulatory and commercial, whereas Cabaletta's are primarily clinical data readouts. Risk factors differ accordingly—financing and execution risk weigh more on Cabaletta, while regulatory and combination-safety outcomes loom larger for Cullinan. Both stocks remain sensitive to broad biotech sector sentiment and technical selling.
Tickeron AI Verdict
Based on observable factors, Tickeron's AI would likely lean toward CGEM in the current environment. Cullinan's more consistent catalyst cadence, late-stage regulatory progress, diversified pipeline, and larger institutional footprint generally translate into stronger trend consistency and relative positioning. Cabaletta's concentrated, earlier-stage profile can generate outsized moves but also introduces greater event-driven volatility and financing sensitivity. Accordingly, an AI framework prioritizing trend stability, catalyst density, and breadth of risk would probabilistically favor Cullinan, while recognizing that both names remain high-volatility, news-dependent holdings.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CABA is a Buy and CGEM is a Buy.
CABA in +8.94% Uptrend, rising for three consecutive days on October 29, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where CABA advanced for three days, in 218 of 247 cases, the price rose further within the following month. The odds of a continued upward trend are 88%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where CABA's RSI Oscillator exited the oversold zone, 20 of 26 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 44 of 60 cases where CABA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 73%.
The Moving Average Convergence Divergence (MACD) for CABA just turned positive on October 22, 2026. Looking at past instances where CABA's MACD turned positive, the stock continued to rise in 38 of 49 cases over the following month. The odds of a continued upward trend are 78%.
CABA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CABA as a result. In 77 of 92 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 84%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CABA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for CABA entered a downward trend on November 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 10 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 31 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 52 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.151) is normal, around the industry mean (3.104). P/E Ratio (-1.036) is within average values for comparable stocks, (-0.958). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (129.907) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (439.647).
The Tickeron Price Growth Rating for this company is 85 (best 1 - 100 worst), indicating slightly worse than average price growth. CABA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CABA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
CGEM in upward trend: price may ascend as a result of having broken its lower Bollinger Band on October 16, 2026
CGEM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 30 of 35 cases where CGEM's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where CGEM's RSI Indicator exited the oversold zone, 21 of 25 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 84%.
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on CGEM as a result. In 74 of 96 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 77%.
The Moving Average Convergence Divergence (MACD) for CGEM just turned positive on October 20, 2026. Looking at past instances where CGEM's MACD turned positive, the stock continued to rise in 41 of 52 cases over the following month. The odds of a continued upward trend are 79%.
Following a +7.02% 3-day Advance, the price is estimated to grow further. Considering data from situations where CGEM advanced for three days, in 205 of 269 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 50 of 57 cases where CGEM's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CGEM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for CGEM entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 26 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 33 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.986) is normal, around the industry mean (3.104). P/E Ratio (-4.801) is within average values for comparable stocks, (-0.958). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (129.907) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (439.647).
The Tickeron Price Growth Rating for this company is 42 (best 1 - 100 worst), indicating steady price growth. CGEM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CGEM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
CABA | CGEM | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 5 | 28 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 52 Fair valued | 33 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 98 | 98 | |
PRICE GROWTH RATING 1..100 | 85 | 42 | |
P/E GROWTH RATING 1..100 | 10 | 26 | |
SEASONALITY SCORE 1..100 | 31 | 90 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
CGEM's Valuation (33) in the null industry is in the same range as CABA (52). This means that CGEM’s stock grew similarly to CABA’s over the last 12 months.
CGEM's Profit vs Risk Rating (100) in the null industry is in the same range as CABA (100). This means that CGEM’s stock grew similarly to CABA’s over the last 12 months.
CGEM's SMR Rating (98) in the null industry is in the same range as CABA (98). This means that CGEM’s stock grew similarly to CABA’s over the last 12 months.
CGEM's Price Growth Rating (42) in the null industry is somewhat better than the same rating for CABA (85). This means that CGEM’s stock grew somewhat faster than CABA’s over the last 12 months.
CABA's P/E Growth Rating (10) in the null industry is in the same range as CGEM (26). This means that CABA’s stock grew similarly to CGEM’s over the last 12 months.
| CABA | CGEM | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 77% | 2 days ago 84% |
| Stochastic ODDS (%) | 2 days ago 73% | 2 days ago 88% |
| Momentum ODDS (%) | 2 days ago 84% | 2 days ago 77% |
| MACD ODDS (%) | 2 days ago 78% | 2 days ago 79% |
| TrendWeek ODDS (%) | 2 days ago 87% | 2 days ago 77% |
| TrendMonth ODDS (%) | 2 days ago 88% | 2 days ago 75% |
| Advances ODDS (%) | 6 days ago 88% | 7 days ago 76% |
| Declines ODDS (%) | 2 days ago 90% | 2 days ago 87% |
| BollingerBands ODDS (%) | 2 days ago 85% | 2 days ago 86% |
| Aroon ODDS (%) | 2 days ago 85% | 2 days ago 85% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CABA’s FA Score shows that 1 FA rating(s) are green while CGEM’s FA Score has 2 green FA rating(s).
- CABA’s FA Score: 1 green, 4 red.
- CGEM’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CABA’s TA Score shows that 5 TA indicator(s) are bullish while CGEM’s TA Score has 5 bullish TA indicator(s).
- CABA’s TA Score: 5 bullish, 3 bearish.
- CGEM’s TA Score: 5 bullish, 3 bearish.
Price Growth
CABA (@Biotechnology) experienced а +5.93% price change this week, while CGEM (@Biotechnology) price change was +2.68% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -2.06%. For the same industry, the average monthly price growth was -12.02%, and the average quarterly price growth was -17.00%.
Reported Earning Dates
CABA is expected to report earnings on Nov 09, 2026.
CGEM is expected to report earnings on Nov 05, 2026.
Industries' Descriptions
@Biotechnology (-2.06% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
CABA and
Correlation & Price change
A.I.dvisor indicates that over the last year, CABA has been loosely correlated with CGEM. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if CABA jumps, then CGEM could also see price increases.
| Ticker / NAME | Correlation To CABA | 1D Price Change % | ||
|---|---|---|---|---|
| CABA | 100% | -5.30% | ||
| CGEM - CABA | 49% Loosely correlated | -0.67% | ||
| NCEL - CABA | 48% Loosely correlated | -7.45% | ||
| FATE - CABA | 45% Loosely correlated | -3.37% | ||
| RAPP - CABA | 45% Loosely correlated | +0.32% | ||
| EDIT - CABA | 45% Loosely correlated | -3.75% | ||
More | ||||
CGEM and
Correlation & Price change
A.I.dvisor indicates that over the last year, CGEM has been loosely correlated with CABA. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if CGEM jumps, then CABA could also see price increases.
| Ticker / NAME | Correlation To CGEM | 1D Price Change % | ||
|---|---|---|---|---|
| CGEM | 100% | -0.67% | ||
| CABA - CGEM | 49% Loosely correlated | -5.30% | ||
| LXEO - CGEM | 47% Loosely correlated | -2.55% | ||
| RCKT - CGEM | 47% Loosely correlated | +1.23% | ||
| RLAY - CGEM | 46% Loosely correlated | -5.83% | ||
| PRME - CGEM | 46% Loosely correlated | -5.93% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| XAPR | 38.57 | -0.06 | -0.16% |
| FT Vest U.S. Equity Enhance & Moderate Buffer ETF - April (XAPR) | |||
| FISR | 24.85 | -0.10 | -0.40% |
| State Street Fixed Income Sector Rotation ETF (FISR) | |||
| FBCG | 57.56 | -0.84 | -1.44% |
| Fidelity Blue Chip Growth ETF (FBCG) | |||
| ADPV | 43.19 | -0.82 | -1.86% |
| Adaptiv Select ETF (ADPV) | |||
| PANG | 28.87 | -2.50 | -7.97% |
| Leverage Shares 2X Long PANW Daily ETF (PANG) | |||